Research programme: CD40-Fas ligand fusion proteins - Apoxis
Latest Information Update: 23 Nov 2006
At a glance
- Originator Apoxis
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 28 Jun 2004 Preclinical trials in Immunological disorders in Switzerland (unspecified route)